Analysts say the Tubulis platform technologies that yielded these ADCs could also help Gilead develop drugs in other therapeutic areas.Continue reading
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Why Biogen Is Paying $5.6B to Buy Apellis Pharma | 0 | 5 | 03-04-2026 |
| 2 | Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma | 0 | 5 | 09-03-2026 |
| 3 | Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug | 5 | 7 | 07-04-2026 |
| 4 | United Therapeutics Buys Thymmune For Up To $300M | 0 | 5 | 02-07-2026 |
| 5 | Novartis is buying a U.K. cancer drug startup for up to $1.5 billion | 0 | 7 | 06-07-2026 |
| 6 | Anduril Raises $5 Billion In New Round; Company Valuation At $61 Billion | 0 | 7 | 13-05-2026 |
| 7 | Why UHS Is Acquiring Talkspace for $835M | 0 | 5 | 11-03-2026 |
| 8 | Gilat to Acquire Comtech’s Satellite and Space Business, Targeting US Defense Growth | 0 | 5 | 16-06-2026 |
| 9 | Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum And Strong Product-Level Performance Of GRAFAPEX (Treosulfan) For Injection | 5 | 5 | 25-06-2026 |
| 10 | 2 Firms Lead Merck's $11.3B Bio-Techne Life Sciences Deal | 0 | 7 | 25-06-2026 |